RCUS
Source profileArcus Biosciences
Oncology immunotherapy
Company profile
CIK1724521
ExchangeNYSE
SectorHealthcare
Tracked assets1
Pipeline assets
Domvanalimab
Upper GI cancers
Phase 3Phase 3 Readout
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | STAR-221 interim analysis window Phase 3 Readout | Domvanalimab | Phase 3 | Q3 2026 | quarter | upcoming |
SEC filings
No sample filings for this company.
Press releases
No sample press releases for this company.
ClinicalTrials.gov studies
No linked sample studies for this company.
Change history
No sample changes yet.